Pluri (FRA:4DX) Scaled Net Operating Assets: 0.37 (As of Mar. 2026)


FRA:4DX Pluri Inc FRA:4DX
25 GF Score
Price €5.60
GF Value €17.84
! 6 Warning Signs
View Full Analysis

What is Pluri Scaled Net Operating Assets?

Pluri FRA:4DX 25 Scaled Net Operating Assets is 0.37 as of Mar. 2026. GuruFocus rates FRA:4DX with a GF Score™ of 25/100 and a GF Value™ of €17.84. The stock has 6 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Pluri's operating assets for the quarter that ended in Mar. 2026 was €14.48 Mil. Pluri's operating liabilities for the quarter that ended in Mar. 2026 was €4.70 Mil. Pluri's Total Assets for the quarter that ended in Dec. 2025 was €26.13 Mil. Therefore, Pluri's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.37.


Pluri Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Pluri's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pluri Scaled Net Operating Assets Chart

Pluri Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.07 0.07 0.10 0.30

Pluri Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.32 0.34 0.39 0.37

FRA:4DX vs MRKR, VYNE, LGVN: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Pluri's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pluri Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Pluri's Scaled Net Operating Assets falls into.


FRA:4DX
25GF Score
Pluri Inc FRA:4DX
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pluri Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Pluri's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2025 )
=(Operating Assets (A: Jun. 2025 )-Operating Liabilities (A: Jun. 2025 ))/Total Assets (A: Jun. 2024 )
=(15.667-4.767)/36.721
=0.30

where

Operating Assets(A: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=33.538 - 17.871
=15.667

Operating Liabilities(A: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=34.288 - 5.29 - 24.231
=4.767

Pluri's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(14.475-4.695)/26.129
=0.37

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=22.539 - 8.064
=14.475

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=33.783 - 4.844 - 24.244
=4.695

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.37 mean?
Pluri (FRA:4DX) has a Scaled Net Operating Assets of 0.37 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Pluri and its competitors.
Is Pluri's Scaled Net Operating Assets too high?
Pluri's current Scaled Net Operating Assets is 0.37. Overall, Pluri has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Pluri's Scaled Net Operating Assets compare to MRKR and VYNE?
Pluri's Scaled Net Operating Assets of 0.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Pluri and its competitors. Pluri's current Scaled Net Operating Assets is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Pluri (FRA:4DX) has a current Scaled Net Operating Assets of 0.37. The stock's GF Value™ is €17.84, compared to a current price of €5.60 — trading 68.6% below its estimated fair value. The current Scaled Net Operating Assets is 0.37. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Pluri (FRA:4DX), the current Scaled Net Operating Assets is 0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pluri (FRA:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of €5.60 is trading 68.6% below its estimated GF Value™ of €17.84.

Key valuation signals for FRA:4DX:

  • Scaled Net Operating Assets: 0.37
  • GF Value™: €17.84 vs. price of €5.60 (68.6% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pluri Business Description

Other Exchanges PLUR:USAPLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for FRA:4DX

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price
€17.84
GF Value